Ongoing HIV dissemination during HAART

Nature Medicine

Volumn 5, Issue 10, 1999, Pages 1099-1104

  Grossman, Zvi ^a   Polis, Michael ^b   Feinberg, Mark B ^c   Grossman, Zehava ^d   Levi, Itschak ^d   Jankelevich, Shirley ^e   Yarchoan, Robert ^e   Boon, Jacob ^f   De Wolf, Frank ^g   Lange, Joep M A ^g   Goudsmit, Jaap ^g   Dimitrov, Dimiter S ^f   Paul, William E ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c EMORY UNIVERSITY   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

^e NATIONAL CANCER INSTITUTE   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; GROWTH INHIBITION; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMORY CELL; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEINASE INHIBITION; T LYMPHOCYTE ACTIVATION; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; MODELS, IMMUNOLOGICAL; RNA, VIRAL; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0032828952     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/13410     Document Type: Note

References (26)

1. Ho, D.D.et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
2. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
3. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 271, 1582-1586 (1996).
4. Perelson, A.S. et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191 (1997).
5. Grossman, Z., Feinberg, M., Kuznetsov, V., Dimitrov, D. & Paul, W. HIV infection: how effective is drug combination treatment? Immunol. Today 19, 528-532 (1998).
6. Kim, S., Byrn, R., Groopman, J. & Baltimore, D. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J. Virol. 63, 3708-3713 (1989).
7. Dimitrov, D.S. et al. Quantitation of HIV-1 infection kinetics. J. Viral. 67, 2182-2190 (1993).
8. Cavert, W. et al. Kinetics of response in lymphoid tissues to anti-retroviral therapy of HIV-1 infection. Science 276, 960-964 (1997); erratum: 276, 1321 (1997).
9. Mueller, B.U. et al. Individual prognoses of long-term responses to anti-retroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy. AIDS 12, F191-F196 (1998).
10. Igarashi, T. et al. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nature Med. 5, 211-216 (1999).
11. Zhang, L. et al. Rapid clearance of simian immunodeficiency virus particles from plasma of rhesus macaques. J. Virol, 73, 855-856 (1999).
12. Grossman, Z., Feinberg, M.B. & Paul, W.E. Multiple modes of cellular activation and virus transmission in HIV infection: a role for chronically and latently infected cells in sustaining viral replication. Proc. Natl. Acad. Sci. USA 95, 6314-6319 (1998).
13. Grossman, Z., Herberman, R.B. & Dimitrov, D. T Cell turnover in SIV infection. Science 284, 555a-555b (1999).
14. Cheynier, R. et al. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell 78, 373-387 (1994).
15. Cheynier, R. et al. Antigenic stimulation by BCG vaccine as an in vivo driving force for SIV replication and dissemination. Nature Med. 4, 421-427 (1998).
16. Autran, B. et al. Positive effects of combined anti-retroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277, 112-116 (1997).
17. Chun, T.W. et al. Presence of an inducible HIV-1 latent reservoir during highly active anti-retroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193-13197 (1997).
18. Harrigan, P.R., Whaley, M. & Montaner, J.S.G. Rate of HIV-1 RNA rebound upon stopping anti-retroviral therapy. AIDS 13, F59-F62(1999).
19. Zhang, L. et al. Quantifying residual HIV-1 replication in patients receiving combination anti-retroviral therapy. N. Engl. J. Med. 340, 1605-1613 (1999).
20. Furtado, M.R. et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent anti-retroviral therapy. N. Engl. J. Med. 340, 1614-1622 (1999).
21. Bucy, R.P. Immune clearance of HIV type 1 replication-active cells: a model of two patterns of steady state HIV infection. AIDS Res. Hum. Retroviruses 15, 223-227 (1999).
22. Grossman, Z. and Herberman, R.B. T-cell homeostasis in HIV infection is neither failing nor blind: modified cell counts reflect an adaptive response of the host. Nature Med. 3, 486-490 (1997).
23. Reijers, M.H. et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam duration of anti-retroviral medication (ADAM) study. Lancet 352, 185-190 (1998).
24. Pialoux, G. et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N. Engl. J. Med. 339, 1269-1276 (1998).
25. Havlir, D.V. et al. Maintenance anti-retroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS clinical trials group study 343 team. N. Engl. J. Med. 339, 1261-1268 (1998).
26. Bonhoeffer, S., May, R.M., Shaw, G.M. & Nowak, M.A. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA 94, 6971-6976 (1997).